Management of Benign Prostatic Hypertrophy (Current Clinical Urology)

A concise, up-to-date review of the many new therapies available for the treatment of benign prostatic hypertrophy (BPH). The authors concisely evaluate the latest minimally invasive therapies, as well as time-tested surgical treatments, and review the medical therapies for BPH, namely a-adrenergic antagonists, 5-a reductase inhibitors, and their therapeutic combinations. Additional chapters examine the pathophysiology and natural history of BPH, its epidemiology, and the urodynamic evaluation of lower urinary tract symptoms. A perfect reference source for the practicing urologist seeking sound guidance on the best approach to his patients.

Numerous recent advances in the medications and technologies available to treat benign prostatic hyperplasia (BPH) raise many questions for practicing urologists seeking optimal therapies for their patients. In Management of Benign Prostatic Hypertrophy, a panel of internationally recognized expert clinicians and investigators in urology review the new treatments in the light of established urologic principles and tradition. The authors concisely evaluate the latest minimally invasive therapies, as well as time-tested surgical treatments, and review the medical therapies for BPH, namely a-adrenergic antagonists, 5a-reductase inhibitors, and their therapeutic combinations. Additional chapters examine the pathophysiology and natural history of BPH, its epidemiology, and the urodynamic evaluation of lower urinary tract symptoms, with special attention given to a more current understanding and treatment of postobstructive diuresis, a significant medical complication and frequent source of urologic consultation.
Grounded in the principles and hallmarks of urology, Management of Benign Prostatic Hypertrophy satisfies the needs of practicing urologists seeking a concise up-to-date interpretation and analysis of the many new therapies available for the treatment of BPH.